Drug intelligence / Profile preview

Cellgram-AKI

Development stage: Unknown
Lead developer: Pharmicell
Modality: Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intrathecal, Intravenous

Overview

Cellgram-AKI is an allogeneic bone marrow-derived mesenchymal stem cell (MSC) therapy developed by Pharmicell Co. Ltd. It was initially developed for the treatment of acute kidney injury (AKI), a rapid decline in kidney function often caused by ischemia-reperfusion injury. The therapy works through multiple mechanisms, including anti-inflammatory effects, anti-apoptotic actions, promotion of angiogenesis, reduction of oxidative stress, prevention of fibrosis, and immunomodulation. Cellgram-AKI also received temporary approval in South Korea in 2020 for the treatment of severe pneumonia in COVID-19 patients, with extended approval in 2021, leveraging its anti-inflammatory properties to prevent cytokine storm-related symptoms.

Beyond the preview

Go deeper on Cellgram-AKI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellgram-AKI.

Explore the full profile